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Construct  Fragments  5' Primer  3' Primer  Tm of rxn °C IA (955)  W95  W79  60 
I (4166)  IB (3211)  W80  W92  60 IIA (756)  W91  W87  60 IIAB (2486)  IIB (1730)  W88  W83  60 
II (4422)  IXB (1936)  W84  W92  62 IIIA (756)  W91  W87  60 
III (4284)  IIIB (3528)  W88  W96  60 
IVA (1882)  W118  W126  60 
IV (4166)  IVB (2275)  W125  W121  60 VA (1692)  W91  W85  60 VAB (2495)  VIIC (803)  W86  W83  62 
V (4431)  IXB (1936)  W84  W92  62 
VIA (1692)  W91  W85  60 
VI (4293)  VIB (2601)  W86  W96  60 VIIA (955)  W95  W79  60 VIIAB (1890)  VIIB (935)  W80  W85  60 VIIC (803)  W86  W83  60 
VII (4629)  VIICD (2739)  IXB (1936)  W84  W92  62 VIIIA (1119)  W91  W89  60 
VIII (4297)  VIIIB (3178)  W90  W96  60 IXA (2686)  W95  W83  62 

































Line  Chorion  Stage 10 follicular localization  GFP 1FV‐MA       2FV‐FA       13FNV‐MA LY       13FNV‐MA DY       14FNV‐MA  Dorsalized  Yes  + 16FNV‐MA  Dorsalized  Yes‐ Particular follicular cells  + 26M‐FA       27M‐MA 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Images indicative of the overall results can be seen in Figures 16 and 17.  DER‐GFP containing flies were also tested controls. Dorsalized phenotypes ranged from normally dorsalized (similar phenotype to that of overexpressed DER) to severely dorsalized, in which the appendages are barely notable.  Line 16FNV‐MA stage 10 ovaries had a particular follicular expression pattern, due likely to the location of chimeric construct insertion. A unique expression pattern was also seen in the dorsal/ventral patches of eye color expression in the mature transgenic flies.  
 
 
 
 
Figure 16. Chorion images of CY2GAL chimeric construct misexpression.     
  
 
Figure 17. Stage 10 egg chamber images of CY2GAL chimeric construct 
misexpression. 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Co­transfections –Blot Results 
  In preparation for the in vitro co‐immunoprecipitation assay, co‐transfections were carried out with DER‐V5 + Kek1‐GFP, ErbB2‐V5 + Kek1‐GFP, ErbB2SI‐IVa‐V5 + Kek1‐GFP, and DERSI‐IVa‐V5 + Kek1‐GFP.  Cells were then pelleted, lysed, and examined using a Western Blot (Materials and Methods).  Membranes were probed with anti‐V5 antibody to visualize the receptors, and anti‐GFP antibody to visualize Kek1 (Figure 18). Note that the Kek1 band appears to be missing from the DER/Kek1 co‐transfection. However, this is likely due to an experimental error in the Western procedure rather than the transfection itself, as GFP was seen in those cells prior to pelleting.  
               
 
Figure 18. Anti­V5 / Anti­GFP Western blots of co­transfections  
Co­Immunoprecipitation­ Hypothetical Results 
 
                        
 
  Figure 19. Structure of variants (Red represent DER, blue is ErbB2) 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If extracellular domains IVb‐V are necessary and sufficient for DER binding to Kek1, as they are believed to be, then DERSI‐IVa will be able to bind Kek1 successfully in the co‐immunoprecipitation assay (see Figure 19 for reference). Conversely, ErbB2SI‐Iva will 
not be able to Kek1, as it is lacking these crucial DER domains. Using DER‐V5 and ErbB2‐V5 as positive and negative controls (see Materials and Methods for constructs used in co‐transfections), the hypothesized Western blot results obtained from this assay can be seen in Figure 20 below.   
 
 
            
 
Figure 20: Hypothetical Western Blots for Co­Immunoprecipitation Studies 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DISCUSSION 
 If properly understood, the DER/Kek1 interaction could potentially lead to the creation of a modified Kek1 or Kek1‐based peptides specifically targeted for the human Epidermal Growth Factor receptors.  As the members of the EGFR family in humans are often overexpressed in cancer cells, such a biologic could act to directly bind and inhibit receptor activation and signaling.  Previous studies done in the Duffy lab (K. Cook and J.B. Duffy, personal communication) have demonstrated that domain V of DER is necessary for the interaction between DER/Kek1.  Its deletion from DER leads to a dramatic decrease in binding affinity for Kek1. Though informative, deletion studies like this one are not the optimal approach for exploring protein‐protein interactions, as such deletions may also disrupt secondary and tertiary protein structure. Further experiments show that addition of domain V onto ErbB1 does not confer binding affinity.  While swapping domains in this manner is a better way to examine protein‐protein interactions, the swapping partners must be close in structure in order for proper protein folding to be maintained. Recently published data from Alvarado et. al shows that ErbB1 and DER are not as structurally similar as was once thought. Rather, ErbB2 more closely resembles DER, both in the lack of an autoinhibitory domain II/IV tether, and in the presence of other stabilizing autoihibitory interactions between domains I/II and I/III.  Current functional studies are being conducted in the Duffy lab using domain swaps between Kek1 and other members of the LIG family in order to determine which domains of Kek1 are necessary or sufficient for binding to DER.  I adopted a complementary approach to studying this interaction, by creating domain swaps between DER and its human homolog ErbB2 in order to establish which domains of DER are necessary and/or sufficient for binding to Kek1. A series of nine DER/ErbB2 chimeric receptors were designed, two of which were successfully generated.  Specific extracellular domain boundaries were obtained from Diego Alvarado.  Upon his recommendation, domains II and IV were split into IIa/IIb and IVa/IVb, where the a notation is indicative of a portion of the domain that may in fact 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belong to the previous domain based on structural studies. For example, it is believed that domain III actually encompasses the IVa fragment, and domain IV is made up of IVb only.  Stitching PCR was used to create the receptor variants, a method that often resulted in low yields of the desired products, thus it was difficult to obtain a large enough quantity of the stitched PCR product to be used in the Gateway BP cloning reaction.  To overcome this, various permutations in temperature, primer/template concentrations, cycling conditions, and buffer reagents – Mg and DMSO were tried with varying degrees of success.  To alleviate such problems in the future, increasing the Tm’s of the primers might be an additional alteration.  Increasing the stringency (annealing temp.) may help reduce the number of nonspecific bands, and thereby increase yield of the desired product. Other techniques that can be employed in the future are digestion ligations, and site‐directed mutagenesis. The UAS‐DERSI‐IVa‐GFP construct was the only one injected into flies for in vivo testing, as it was the only one successfully generated at the time.  Eight independent fly lines were obtained and mapped to assure that expression patterns were due to the receptor’s activity, not to the insertion location of the chimeric construct.  The UAS‐DERSI‐IVa‐GFP transgene was subsequently missexpressed in flies using the UAS‐GAL4 system, specifically in the eyes with the GMRGAL4 driver and in the ovaries with the CY2GAL4.  The rough eye phenotype that was obtained with GMR, and the dorsalized chorion phentoype that was obtained with CY2, both show that the chimeric protein is made properly and exhibits signaling activity.  Similar phenotypes are also observed with DER overexpression in the same tissues.  Upon examination of stage 10 egg chambers from the flies misexpressing DERSI‐IVa‐GFP, it was found that the protein localizes to the apical side of the follicle cells, similar to that for DER‐GFP.  Collectively, these results suggest that this particular swap was successful in maintaining the general protein structure, activity, and localization. Further in vivo studies with the rest of the receptor variants in the series will continue to help define the sequence elements in DER critical for its interaction with Kek1. It is worthy to note that there is some variation in the results (severity of dorsalization / pattern of localization). This is likely due to the chromosomal insertion location of the transgene in various lines.  Expression of the transgene may be affected by local chromatin 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structure thereby leading to phenotypic variation.  Additionally, lethality upon misexpression with CY2GAL4 of so many insertions can be explained by the importance of proper regulation of DER activity throughout embryonic, larval and pupal development.  In the future, in vivo studies with CY2GAL4 should also be conducted at 20 C, to reduce the level of misexpression and allow the survival of adult females for activity and localization studies in the egg chamber.  The co‐immunoprecipitation studies have not yet been completed.  However, it is hypothesized that upon examination of the four co‐transfections, DER‐V5(+ control) and DERSI‐IVa‐V5 should both bind Kek1, whereas ErbB2‐V5(‐ control) and ErbB2SI‐IVa‐V5 should not. When blotted with Anti‐V5 antibody, the IP should then yield bands for DER‐V5 and DERSI‐IVa‐V5, and no bands for ErbB2‐V5 and ErbB2SI‐IVa‐V5.  If there is a band present for the ErbB2SI‐IVa‐V5, then its intensity will correlate with the strength of that receptor’s binding to Kek1.  If binding is strong, it will mean that domains I‐IVa of DER are sufficient to confer binding to Kek1.  Blotting with anti‐GFP antibody of the IP should yield bands for every co‐transfection, as Kek1‐GFP will consistently be pulled down by the anti‐GFP antibody in the protein A slurry, regardless of Kek1’s interaction with the receptors. Whole cell lysate will also be examined on a Western blot, to ascertain that the individual proteins are being made and to estimate their amounts.  If, for example, cells are not producing V5‐tagged receptor this would invalidate any IP results, regardless of any putative interaction.  Similarly, if a receptor is being made in great quantities but still no band is visible for the IP results, there is a greater likelihood that this variant lacks affinity for Kek1.      With the completion of the chimeric ErbB2/DER series and its testing both in vivo and in vitro, our understanding of the DER/Kek1 interaction will greatly increase.  Using similar techniques it will then be possible to create an altered Kek1 molecule that can interact with the human receptors, while maintaining its direct inhibitory effect.  This project has set the stage for the receptor’s side of the DER/Kek1 story and has established a core set of techniques used to direct it.  With the hope that ultimately this important and unique interaction may be used as a potential avenue for the development of Kek1 based cancer therapeutics. 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